Compare BridgeBio Pharma Inc (BBIO) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Ishares Msci Brazil ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Ishares Msci Brazil ETF trades at $34. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | EWZ | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $41.75 |
52-Week Low | $47.29 | $27.36 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EWZ trades at $35.34, down 1.31% today, with a bearish technical signal from moving averages. The ETF tracks Brazilian equities, facing headwinds from US tariffs and currency volatility. Recent institutional buying includes Empowered Funds' $3.06 million position (Defense World, Aug 5, 2026), while technical support sits at $34-$35.
Outlook hinges on Brazil's economic policies and commodity prices. Opportunities exist if rate cuts continue, but risks include political uncertainty and competitive pressure from lower-fee alternatives like FLBR. The dividend yield of approximately 3.78% provides income, but consistency is challenged by reliance on commodity-driven holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
